Tumour necrosis factor blockade and the risk of osteoporosis: Back to the future

Arthritis Research and Therapy

Volumn 9, Issue 4, 2007, Pages

  Sambrook, Philip ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; INFLIXIMAB; METHOTREXATE; OSTEOCALCIN; PENICILLAMINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

BONE DENSITOMETRY; BONE DENSITY; CASE CONTROL STUDY; EDITORIAL; FEMUR NECK; HUMAN; LUMBAR SPINE; MONOTHERAPY; OSTEOPOROSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; DRUG ANTAGONISM; DRUG EFFECT; LUMBAR VERTEBRA; METABOLISM; NOTE; PATHOLOGY; RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548444980     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2277     Document Type: Editorial

References (13)

1. Sambrook PN Eisman JA Champion GD Pocock NA Eberl S Yeates MG Determinants of axial bone loss in rheumatoid arthritis Arthritis Rheum 1987 30 721-728 10.1002/art.1780300701 3619959
2. Goldring SR Gravallese EM Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications Arthritis Res 2000 2 33-37 129989 11094416 10.1186/ar67
3. Sambrook PN The skeleton in rheumatoid arthritis: Common mechanisms for bone erosion and osteoporosis? J Rheumatol 2000 27 2541-2542 11093430
4. Eghbali-Fatourechi G Khosla S Sanyal A Boyle WJ Lacey DL Riggs BL Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 2003 111 1221-1230 152939 12697741 10.1172/JCI200317215
5. Boyle WJ Scott Simonet W Lacey DL Osteoclast differentiation and activation Nature 2003 423 337-342 10.1038/nature01658 12748652
6. Marotte H Pallot-Prades B Grange L Gaudin P Alexandre C Miossec P A one year case control study in rheumatoid arthritis patients indicates a prevention of bone mineral density loss in both responders and non responders to infliximab Arthritis Res Ther 2007 9 R61 10.1186/ar2219 17597527
7. Lange U Teichmann J Muller-Ladner U Strunk J Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF alpha antibody: A prospective open label pilot study Rheumatology 2005 44 1546-1548 10.1093/rheumatology/kei082 16263785
8. Vis M Havaardsholm EA Haugeberg G Uhlig T Voskuyl AE van de Stadt RJ Dijkmans BA Woolf AD Kvien TK Lems WF Evaluation of bone mineral density, bone metabolism, osteoprote-gerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis Ann Rheum Dis 2006 65 1495-1499 10.1136/ard.2005.044198 16606653
9. Seriolo B Paolino S Sulli A Ferretti V Cutolo M Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis Ann NY Acad Sci 2006 1069 420-427 10.1196/annals.1351.040 16855169
10. Schorn D Mowat AG Penicillamine in rheumatoid arthritis: Wound healing, skin thickness and osteoporosis Rheumatol Rehabil 1977 16 223-230 601432
11. Schorn D Osteoporosis in the rheumatoid hand - the effects of treatment with D-penicillamine and oral gold salts S Afr Med J 1983 63 121-123 6401365
12. Kalla AA Meyers OL Chalton D Heath S Brown GMM Smith PR Burger MC Increased metacarpal bone mass following 18 months of slow acting antirheumatic drugs for rheumatoid arthritis Br J Rheumatol 1991 30 91-100 10.1093/rheumatology/30.2.91 2012963
13. Black DM Palermo L Sorensen T Jorgensen JT Lewis C Tylavsky F Wallace R Harris E Cummings SR A normative reference database study for Pronosco X-posure System J Clin Densitom 2001 4 5-12 11393145 10.1385/JCD:4:1:05